Skip to main content
SpringerLink
Log in

Digoxin use in AF increases risk of death

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Washam JB, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Internet Document : 6 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)61836-5

    Google Scholar 

  2. Khan SS, et al. Digoxin use in atrial fibrillation: a critical reappraisal. Lancet : 6 Mar 2015. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(14)62301-1

    PubMed Central  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Digoxin use in AF increases risk of death. Reactions Weekly 1543, 11 (2015). https://doi.org/10.1007/s40278-015-8635-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-8635-z

Search

Navigation